Studying blood markers in cancer patients on immunotherapy

This study uses detailed “single-cell” testing to look for markers that can predict how well immunotherapy works and what side effects may happen. It is for people with non-small cell lung cancer starting standard first-line treatment.

This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.

This study asks people with cancer about their experiences when joining an immunotherapy (a cancer treatment that helps the immune system fight cancer) clinical trial. It may help the researchers understand what patients experience during these trials and improve how trials support patients.

This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.

This study watches immune system markers to see if they can predict which patients will respond well to immunotherapy and who might have side effects. If you have cancer and are starting immunotherapy, this trial may help guide future treatment decisions.

This study is looking at a specific type of immune cell (called TLR4+ cells) in the blood of people with solid tumors. By studying these cells, researchers hope to learn more about how the immune system reacts to cancer and to treatments.